ATSN-101 demonstrated clinically meaningful improvements in …
News
July, 29 2021 • Articles
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing
July 29th, 2021 - Source: Inside Philanthropy
Since its establishment in 1971 by a group of families affected by retinal disease, the Foundation Fighting Blindness has funded research into several of the most serious and common of these conditions, like macular degeneration and retinitis pigmentosa. The foundation grew to become the leading private funder of basic research into conditions that cause blindness and vision loss for more than 10 million Americans and millions more worldwide. In its 50 years in operation, the foundation has raised over $816 million to support research—including the identification of key genes linked to retinal diseases—that has enabled the launch of dozens of clinical trials to test possible treatments. All in all, a solid track record.
Click here for the rest of the article
09/27/2022
Opus Genetics Expands Board of Directors with Appointment of Global…
RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE…
09/15/2022
RD Fund Participates in a €75 Million Series B for SparingVision
Proceeds to fund first, in-human trials of breakthrough gene…
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Pa…
- In line with corporate strategy update in April, ProQR to f…
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory…
World-class facility supports the company’s growth, and disc…
07/21/2022
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-C…
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrie…
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developi…
06/21/2022
Foundation Fighting Blindness Announces Leadership Changes
Jason Menzo named chief executive officer
Russell Kelley, Ph…
06/15/2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing…
Funds to support advancement of two clinical trials t…
05/11/2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-b…
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and…
Trial recruitment is enabled by the Foundation Fighting Blin…